Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer

被引:15
作者
Kassouf, W
Ismail, HRA
Aprikian, AG
Chevalier, S
机构
[1] McGill Univ, Ctr Hlth, Res Inst, Urol Oncol Res Grp, Montreal, PQ H3G 1A4, Canada
[2] McGill Univ, Ctr Hlth, Dept Surg, Div Urol, Montreal, PQ H3G 1A4, Canada
[3] McGill Univ, Ctr Hlth, Dept Med & Oncol, Montreal, PQ H3G 1A4, Canada
关键词
prostatic stroma; prostatic epithelium; angiogenesis; endoglin; transforming growth factor-beta;
D O I
10.1038/sj.pcan.4500716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Endoglin is a nonsignaling receptor for transforming growth factor that contributes to the action of this growth factor in diverse cell types. It may also exhibit a function of its own. Endoglin levels vary with disease states and is a marker of new blood vessels. We studied endoglin expression in whole-mount prostate sections from 64 patients with localized prostate cancer, assessing reactivity in the epithelium, the stroma, and blood vessels. Cells in normal/benign acini were negative but significantly immunoreactive (P<0.001) in both prostatic intraepithelial neoplasia (PIN; 52% of cases) and malignant areas (77% of cases). In tumors, this involved less than 25% of malignant cells in 59% of specimens. The endoglin-stained stroma was detected mainly in areas surrounding PIN acini and tumors. Endoglin antibodies detected more microvessels than von Willebrand Factor antibodies in all prostatic areas (P < 0.01). In addition, the number of microvessels increased with the development of cancer and correlated with Gleason score (P < 0.01). Changes in endoglin expression in PIN and malignant cells, the surrounding stroma, and related blood vessels, suggest that endoglin function may be altered in prostate cancer.
引用
收藏
页码:105 / 110
页数:6
相关论文
共 34 条
[1]   Estimation of angiogenesis with anti-CD105 immunostaining in the process of colorectal cancer development [J].
Akagi, K ;
Ikeda, Y ;
Sumiyoshi, Y ;
Kimura, Y ;
Kinoshita, J ;
Miyazaki, M ;
Abe, T .
SURGERY, 2002, 131 (01) :S109-S113
[2]   Expression and structural features of endoglin (CD105), a transforming growth factor beta 1 and beta 3 binding protein, in human melanoma [J].
Altomonte, M ;
Montagner, R ;
Fonsatti, E ;
Colizzi, F ;
Cattarossi, I ;
Brasoveanu, LI ;
Nicotra, MR ;
Cattelan, A ;
Natali, PG ;
Maio, M .
BRITISH JOURNAL OF CANCER, 1996, 74 (10) :1586-1591
[3]   A murine model of hereditary hemorrhagic telangiectasia [J].
Bourdeau, A ;
Dumont, DJ ;
Letarte, M .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (10) :1343-1351
[4]   Endoglin expression as a measure of microvessel density in cervical cancer [J].
Brewer, CA ;
Setterdahl, JJ ;
Li, MJ ;
Johnston, JM ;
Mann, JL ;
Mcasey, ME .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (02) :224-228
[5]  
Burrows FJ, 1995, CLIN CANCER RES, V1, P1623
[6]  
CANNIGIA I, 1997, ENDOCRINOLOGY, V138, P4977
[7]  
CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027
[8]   CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas - Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients [J].
Dales, JP ;
Garcia, S ;
Bonnier, P ;
Duffaud, F ;
Andrac-Meyer, L ;
Ramuz, O ;
Lavaut, MN ;
Allasia, C ;
Charpin, C .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2003, 119 (03) :374-380
[9]  
FREGENE TA, 1993, ANTICANCER RES, V13, P2377
[10]  
FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493